title: Liver transplantation for neuroendocrine tumour liver metastases.
abstract: OBJECTIVE
  Search and review of available literature were made to define the indications for and timing of liver transplantation for neuroendocrine tumour (NET) liver metastases.
  
  
  METHODS
  Electronic bibliographical databases were searched. Prospective and retrospective cohort studies and case-controlled studies were used for qualitative and quantitative synthesis of the systematic review. Reports of patients with liver transplantation alone for NET liver metastases of any origin or combined with resection of extrahepatic tumour deposits were recruited.
  
  
  RESULTS
  The number of patients who have undergone liver transplantation for NET liver metastases is 706. The post-transplant 5-year survival rate from the time of diagnosis was approximately 70%. NET patients with metastases confined to the liver and not poorly differentiated are favourable candidates for liver transplantation. Selection of patients based on evolution of tumours over 6 months is not recommended.
  
  
  CONCLUSIONS
  Non-resectable NET liver metastasis resistant to medical treatment and confined to the liver is an accepted indication for liver transplantation.
authors.affiliation: Department of Surgery, The University of Hong Kong, and Liver Surgery Centre, Hong Kong Sanatorium and Hospital, Hong Kong.
authors.forename: Sheung Tat
authors.initials: ST
authors.lastname: Fan
authors.forename: Yves Patrice
authors.initials: YP
authors.lastname: Le Treut
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Mazzaferro
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Burroughs
authors.forename: Michael
authors.initials: M
authors.lastname: Olausson
authors.forename: Stefan
authors.initials: S
authors.lastname: Breitenstein
authors.forename: Andrea
authors.initials: A
authors.lastname: Frilling
mesh_terms: D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality; D018358:Neuroendocrine Tumors / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D018579:Patient Selection; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome